Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Milei Threatens Falkland Oil Firms With Sanctions 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Add as a preferred source on Google
SAN DIEGO, Feb. 28, 2018 -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday, March 14, 2018 at 3:50 p.m. ET.
A live webcast of the presentation will be available at ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease and glomerulonephritis, respectively. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam® and Thiola®.
Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
760-260-8600
[email protected]
